WCN26-2518 INDUCIBLE EXON SKIPPING AFTER DISEASE ONSET AS A THERAPEUTIC STRATEGY FOR CKD: EVALUATION IN A PATIENT-DERIVED MOUSE MODEL OF ALPORT SYNDROME

Read full text Summarise with VIRAT
Authors: Kentarou Hashikami, Ryosuke Kobayashi, Ryotaro Hori, Kenta Danbayashi, Yasunori Nio
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Alport syndrome (AS) is a progressive hereditary nephropathy caused by mutations in COL4A3, COL4A4, or COL4A5, which encode the α3, α4, and α5 chains of type IV collagen. These mutations disrupt the glomerular basement membrane (GBM), leading to hematuria, proteinuria, and eventual renal failure. Although angiotensin II receptor blockers (ARBs) can delay progression, no curative therapies currently exist. Given the monogenic nature of AS, exon skipping therapy offers a promising mutation-specific strategy to restore functional protein expression.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies RNA Research and Splicing Chronic Kidney Disease and Diabetes

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105090–105090
Publication date
25 March 2026
Language
EN